NCT00057382终止2 期
T138067 Versus Doxorubicin in Chemotherapy-Naive, Unresectable, Hepatocellular Carcinoma Patients
Tularik76 个研究点 分布在 7 个国家目标入组 750 人开始时间: 2003年3月1日最近更新:
适应症
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 终止
- 发起方
- 入组人数
- 750
- 试验地点
- 76
研究概览
简要总结
This is an international, multicenter, randomized study of intravenous T138067 versus intravenous doxorubicin in hepatocellular carcinoma (liver cancer). Patients can not have been treated before with chemotherapy and surgery is not recommended for their cancer. A total of 750 subjects will be enrolled in this study.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •pathologic diagnosis of unresectable HCC
- •chemotherapy-naïve for HCC
- •Child-Pugh Class A or B liver disease
- •measurable disease (i.e., at least one lesion that is at least 20 mm in one dimension) on computerized tomography (CT) scan or magnetic resonance imaging (MRI) or at least one lesion that is at least 10 mm on spiral CT scan
- •Karnofsky Performance Status of ≥ 70%
- •life expectancy of ≥ 12 weeks
- •adequate hematologic function (i.e., absolute neutrophil count [ANC] of ≥ 1500 cells/mm3, platelet count of ≥ 80,000 cells/mm3, hemoglobin of ≥ 8.5 g/dL)
- •total bilirubin of ≤ 1.5 upper limit of normal (ULN)
- •aspartate transaminase (AST) and alanine transaminase (ALT) ≤ 5 ULN
- •serum creatinine of ≤ 2 x ULN
排除标准
- •severe, concurrent disease that would make the subject inappropriate for enrollment
- •Subjects who have received prior intravenous or intra-arterial chemotherapy, chemoembolization, intratumoral ethanol injection, cryosurgery, radiofrequency ablation, or embolization for their HCC. (note: prior surgical resection, immunotherapy, hormonal therapy, radiotherapy, and/or orthotopic liver transplantation are allowed)
- •history of other cancer within the past 5 years other than adequately treated basal cell or squamous cell skin cancer, or carcinoma in situ of the cervix
- •New York Heart Association (NYHA) class III or IV heart disease or a left ventricular ejection fraction of <50% or acute anginal symptoms
- •females who are pregnant or breast-feeding
- •received any investigational agent within 4 weeks of enrollment
- •history of central nervous system metastases or carcinomatous meningitis
- •clinically apparent ascites
- •major surgery within 4 weeks of study enrollment
研究者
研究点 (76)
Loading locations...
相似试验
撤回
1 期
Doxorubicin and Carboplatin in Treating Patients With Recurrent Ovarian CancerOvarian CancerNCT00562185University of Texas Southwestern Medical Center
终止
2 期
Combination Chemotherapy and Dexrazoxane Followed by Surgery and Radiation Therapy in Treating Patients With Advanced Soft Tissue Sarcoma or Recurrent Bone SarcomaSarcomaNCT00544778City of Hope Medical Center7
进行中（未招募）
不适用
iposomial doxorubicin Investigational chemotherapy - Tissue doppler imaging -EvaluatioFirst line treatment on female breast cancerMedDRA version: 6.1Level: PTClassification code 10006199EUCTR2005-003092-20-ITPOLICLINICO UNIVERSITARIO AGOSTINO GEMELLI
Unknown
2 期
Topotecan, Vincristine, and Doxorubicin in Treating Young Patients With Refractory Stage 4 NeuroblastomaNeuroblastomaNCT00392340Children's Cancer and Leukaemia Group63
已完成
3 期
Doxorubicin With or Without Ifosfamide and Pegfilgrastim in Treating Patients With Locally Advanced or Metastatic Soft Tissue SarcomaSarcomaNCT00061984European Organisation for Research and Treatment of Cancer - EORTC455